Market Research

Oncology-Cancer Drugs Market By Drug Class (Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy) , Hormonal Therapy) , By Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cance

Best Price Guarantee Length Publisher Published Date SKU
from $5,769 250 Pages Allied Market Research July, 2024 ALMR19230338
Best Price Guarantee
Price from $5,769
Length 250 Pages
Publisher Allied Market Research
Published Date July, 2024
SKU ALMR19230338

Oncology-Cancer Drugs Market By Drug Class (Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy) , Hormonal Therapy) , By Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, Other Cancers) : Global Opportunity Analysis and Industry Forecast, 2024-2033


The global oncology-cancer drugs market was valued at $167.0 billion in 2023, and is projected to reach $335.2 billion by 2033, growing at a CAGR of 7.2% from 2024 to 2033.
The oncology/cancer drugs encompass pharmaceuticals specifically designed to diagnose, treat, and manage various types of cancer. These drugs target cancerous cells or interfere with processes involved in cancer growth and spread. It includes a wide array of therapeutic approaches, ranging from traditional chemotherapy to more targeted therapies like immunotherapy and precision medicine.
The global oncology-cancer drugs market is driven by rise in incidence of cancer globally due to aging population, lifestyle changes, and environmental exposures, which drives the demand for innovative therapies. This growing patient population highlights the need for continuous R&D efforts to address diverse cancer types and unmet medical needs. Furthermore, progress in the field of science and technology, specifically in disciplines such as molecular biology, genomics, and immunotherapy, are propelling substantial advancements in the development of cancer drugs. The rise of precision medicine strategies, which focus on specific molecular abnormalities that fuel cancer progression, is becoming increasingly prominent. This has resulted in the creation of more potent and less harmful therapies, fueling growth in the oncology drugs market.
However, high development costs of oncology drugs are extensive and costly, often requiring significant investments in preclinical studies, clinical trials, and regulatory approvals which limit the adoption of cancer drugs. Nevertheless, approval from regulatory authorities associated with new treatments and drugs is expected to create several opportunities for the market players. For instance, in October 2023, the U.S. Food and Drug Administration (FDA) approved several new treatments for a range of cancers over the summer. In July, the FDA approved a new indication for Jemperli (dostarlimab) in endometrial cancer. 

Segmentation Overview

The oncology-cancer drugs market is segmented into drug class type, indication, and region. Depending on drug class type, the market is categorized into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. According to indication, it is divided into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

Depending on drug class type, the targeted therapy segment held the largest market share in 2023.
By indication, the breast cancer segment accounted for the highest share in the market in 2023.
Region wise, North America dominated the oncology-cancer drugs market in 2023.

Competitive Scenario

The major players operating in the oncology/cancer drugs market include AbbVie Inc., Amgen, Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, and Pfizer Inc. Other players in oncology/cancer drugs market includes Bayer AG, Regeneron Pharmaceuticals Inc., and Eli Lilly and Company. These players have adopted several strategies, including partnerships, collaborations, and R&D to maintain their position in the competitive market.

Key Market Segments

By Drug Class

Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy

By Indication

Lung Cancer
Stomach Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Liver Cancer
Esophagus Cancer
Cervical Cancer
Kidney Cancer
Bladder Cancer
Other Cancers

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Saudi Arabia
Rest of LAMEA
Key Market Players
AbbVie Inc.
Amgen
Astellas Pharma Inc.
AstraZeneca plc
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Pfizer Inc.


CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS
4.1. Market Overview
4.1.1 Market Size and Forecast, By Drug Class
4.2. Chemotherapy
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Targeted Therapy
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Immunotherapy (Biologic Therapy)
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
4.5. Hormonal Therapy
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, By Region
4.5.3. Market Share Analysis, By Country
CHAPTER 5: ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Indication
5.2. Lung Cancer
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Stomach Cancer
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Colorectal Cancer
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
5.5. Breast Cancer
5.5.1. Key Market Trends, Growth Factors and Opportunities
5.5.2. Market Size and Forecast, By Region
5.5.3. Market Share Analysis, By Country
5.6. Prostate Cancer
5.6.1. Key Market Trends, Growth Factors and Opportunities
5.6.2. Market Size and Forecast, By Region
5.6.3. Market Share Analysis, By Country
5.7. Liver Cancer
5.7.1. Key Market Trends, Growth Factors and Opportunities
5.7.2. Market Size and Forecast, By Region
5.7.3. Market Share Analysis, By Country
5.8. Esophagus Cancer
5.8.1. Key Market Trends, Growth Factors and Opportunities
5.8.2. Market Size and Forecast, By Region
5.8.3. Market Share Analysis, By Country
5.9. Cervical Cancer
5.9.1. Key Market Trends, Growth Factors and Opportunities
5.9.2. Market Size and Forecast, By Region
5.9.3. Market Share Analysis, By Country
5.10. Kidney Cancer
5.10.1. Key Market Trends, Growth Factors and Opportunities
5.10.2. Market Size and Forecast, By Region
5.10.3. Market Share Analysis, By Country
5.11. Bladder Cancer
5.11.1. Key Market Trends, Growth Factors and Opportunities
5.11.2. Market Size and Forecast, By Region
5.11.3. Market Share Analysis, By Country
5.12. Other Cancers
5.12.1. Key Market Trends, Growth Factors and Opportunities
5.12.2. Market Size and Forecast, By Region
5.12.3. Market Share Analysis, By Country
CHAPTER 6: ONCOLOGY-CANCER DRUGS MARKET, BY REGION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Region
6.2. North America
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, By Drug Class
6.2.3. Market Size and Forecast, By Indication
6.2.4. Market Size and Forecast, By Country
6.2.5. U.S. Oncology-Cancer Drugs Market
6.2.5.1. Market Size and Forecast, By Drug Class
6.2.5.2. Market Size and Forecast, By Indication
6.2.6. Canada Oncology-Cancer Drugs Market
6.2.6.1. Market Size and Forecast, By Drug Class
6.2.6.2. Market Size and Forecast, By Indication
6.2.7. Mexico Oncology-Cancer Drugs Market
6.2.7.1. Market Size and Forecast, By Drug Class
6.2.7.2. Market Size and Forecast, By Indication
6.3. Europe
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, By Drug Class
6.3.3. Market Size and Forecast, By Indication
6.3.4. Market Size and Forecast, By Country
6.3.5. Germany Oncology-Cancer Drugs Market
6.3.5.1. Market Size and Forecast, By Drug Class
6.3.5.2. Market Size and Forecast, By Indication
6.3.6. France Oncology-Cancer Drugs Market
6.3.6.1. Market Size and Forecast, By Drug Class
6.3.6.2. Market Size and Forecast, By Indication
6.3.7. UK Oncology-Cancer Drugs Market
6.3.7.1. Market Size and Forecast, By Drug Class
6.3.7.2. Market Size and Forecast, By Indication
6.3.8. Italy Oncology-Cancer Drugs Market
6.3.8.1. Market Size and Forecast, By Drug Class
6.3.8.2. Market Size and Forecast, By Indication
6.3.9. Spain Oncology-Cancer Drugs Market
6.3.9.1. Market Size and Forecast, By Drug Class
6.3.9.2. Market Size and Forecast, By Indication
6.3.10. Rest Of Europe Oncology-Cancer Drugs Market
6.3.10.1. Market Size and Forecast, By Drug Class
6.3.10.2. Market Size and Forecast, By Indication
6.4. Asia-Pacific
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, By Drug Class
6.4.3. Market Size and Forecast, By Indication
6.4.4. Market Size and Forecast, By Country
6.4.5. China Oncology-Cancer Drugs Market
6.4.5.1. Market Size and Forecast, By Drug Class
6.4.5.2. Market Size and Forecast, By Indication
6.4.6. Japan Oncology-Cancer Drugs Market
6.4.6.1. Market Size and Forecast, By Drug Class
6.4.6.2. Market Size and Forecast, By Indication
6.4.7. India Oncology-Cancer Drugs Market
6.4.7.1. Market Size and Forecast, By Drug Class
6.4.7.2. Market Size and Forecast, By Indication
6.4.8. Australia Oncology-Cancer Drugs Market
6.4.8.1. Market Size and Forecast, By Drug Class
6.4.8.2. Market Size and Forecast, By Indication
6.4.9. South Korea Oncology-Cancer Drugs Market
6.4.9.1. Market Size and Forecast, By Drug Class
6.4.9.2. Market Size and Forecast, By Indication
6.4.10. Rest of Asia-Pacific Oncology-Cancer Drugs Market
6.4.10.1. Market Size and Forecast, By Drug Class
6.4.10.2. Market Size and Forecast, By Indication
6.5. LAMEA
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, By Drug Class
6.5.3. Market Size and Forecast, By Indication
6.5.4. Market Size and Forecast, By Country
6.5.5. Brazil Oncology-Cancer Drugs Market
6.5.5.1. Market Size and Forecast, By Drug Class
6.5.5.2. Market Size and Forecast, By Indication
6.5.6. South Africa Oncology-Cancer Drugs Market
6.5.6.1. Market Size and Forecast, By Drug Class
6.5.6.2. Market Size and Forecast, By Indication
6.5.7. Saudi Arabia Oncology-Cancer Drugs Market
6.5.7.1. Market Size and Forecast, By Drug Class
6.5.7.2. Market Size and Forecast, By Indication
6.5.8. Rest of LAMEA Oncology-Cancer Drugs Market
6.5.8.1. Market Size and Forecast, By Drug Class
6.5.8.2. Market Size and Forecast, By Indication
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping Of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. AbbVie Inc.
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. Amgen
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Astellas Pharma Inc.
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. AstraZeneca Plc
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. Bristol-Myers Squibb Company
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. F. Hoffmann-La Roche Ltd.
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Johnson And Johnson
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. Merck And Co., Inc.
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. Novartis AG
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. Pfizer Inc.
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
TABLE 1. GLOBAL ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
TABLE 2. ONCOLOGY-CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY REGION, 2024 - 2033 ($BILLION)
TABLE 3. ONCOLOGY-CANCER DRUGS MARKET FOR TARGETED THERAPY, BY REGION, 2024 - 2033 ($BILLION)
TABLE 4. ONCOLOGY-CANCER DRUGS MARKET FOR IMMUNOTHERAPY (BIOLOGIC THERAPY), BY REGION, 2024 - 2033 ($BILLION)
TABLE 5. ONCOLOGY-CANCER DRUGS MARKET FOR HORMONAL THERAPY, BY REGION, 2024 - 2033 ($BILLION)
TABLE 6. GLOBAL ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 7. ONCOLOGY-CANCER DRUGS MARKET FOR LUNG CANCER, BY REGION, 2024 - 2033 ($BILLION)
TABLE 8. ONCOLOGY-CANCER DRUGS MARKET FOR STOMACH CANCER, BY REGION, 2024 - 2033 ($BILLION)
TABLE 9. ONCOLOGY-CANCER DRUGS MARKET FOR COLORECTAL CANCER, BY REGION, 2024 - 2033 ($BILLION)
TABLE 10. ONCOLOGY-CANCER DRUGS MARKET FOR BREAST CANCER, BY REGION, 2024 - 2033 ($BILLION)
TABLE 11. ONCOLOGY-CANCER DRUGS MARKET FOR PROSTATE CANCER, BY REGION, 2024 - 2033 ($BILLION)
TABLE 12. ONCOLOGY-CANCER DRUGS MARKET FOR LIVER CANCER, BY REGION, 2024 - 2033 ($BILLION)
TABLE 13. ONCOLOGY-CANCER DRUGS MARKET FOR ESOPHAGUS CANCER, BY REGION, 2024 - 2033 ($BILLION)
TABLE 14. ONCOLOGY-CANCER DRUGS MARKET FOR CERVICAL CANCER, BY REGION, 2024 - 2033 ($BILLION)
TABLE 15. ONCOLOGY-CANCER DRUGS MARKET FOR KIDNEY CANCER, BY REGION, 2024 - 2033 ($BILLION)
TABLE 16. ONCOLOGY-CANCER DRUGS MARKET FOR BLADDER CANCER, BY REGION, 2024 - 2033 ($BILLION)
TABLE 17. ONCOLOGY-CANCER DRUGS MARKET FOR OTHER CANCERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 18. ONCOLOGY-CANCER DRUGS MARKET, BY REGION, 2024 - 2033 ($BILLION)
TABLE 19. NORTH AMERICA ONCOLOGY-CANCER DRUGS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 20. NORTH AMERICA ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
TABLE 21. NORTH AMERICA ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 22. U.S. ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
TABLE 23. U.S. ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 24. CANADA ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
TABLE 25. CANADA ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 26. MEXICO ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
TABLE 27. MEXICO ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 28. EUROPE ONCOLOGY-CANCER DRUGS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 29. EUROPE ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
TABLE 30. EUROPE ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 31. GERMANY ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
TABLE 32. GERMANY ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 33. FRANCE ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
TABLE 34. FRANCE ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 35. UK ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
TABLE 36. UK ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 37. ITALY ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
TABLE 38. ITALY ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 39. SPAIN ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
TABLE 40. SPAIN ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 41. REST OF EUROPE ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
TABLE 42. REST OF EUROPE ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 43. ASIA-PACIFIC ONCOLOGY-CANCER DRUGS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 44. ASIA-PACIFIC ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
TABLE 45. ASIA-PACIFIC ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 46. CHINA ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
TABLE 47. CHINA ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 48. JAPAN ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
TABLE 49. JAPAN ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 50. INDIA ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
TABLE 51. INDIA ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 52. AUSTRALIA ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
TABLE 53. AUSTRALIA ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 54. SOUTH KOREA ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
TABLE 55. SOUTH KOREA ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 56. REST OF ASIA-PACIFIC ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
TABLE 57. REST OF ASIA-PACIFIC ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 58. LAMEA ONCOLOGY-CANCER DRUGS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 59. LAMEA ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
TABLE 60. LAMEA ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 61. BRAZIL ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
TABLE 62. BRAZIL ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 63. SOUTH AFRICA ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
TABLE 64. SOUTH AFRICA ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 65. SAUDI ARABIA ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
TABLE 66. SAUDI ARABIA ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 67. REST OF LAMEA ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
TABLE 68. REST OF LAMEA ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 69. ABBVIE INC.: KEY EXECUTIVES
TABLE 70. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 71. ABBVIE INC.: OPERATING SEGMENTS
TABLE 72. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 73. ABBVIE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 74. AMGEN: KEY EXECUTIVES
TABLE 75. AMGEN: COMPANY SNAPSHOT
TABLE 76. AMGEN: OPERATING SEGMENTS
TABLE 77. AMGEN: PRODUCT PORTFOLIO
TABLE 78. AMGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 79. ASTELLAS PHARMA INC.: KEY EXECUTIVES
TABLE 80. ASTELLAS PHARMA INC.: COMPANY SNAPSHOT
TABLE 81. ASTELLAS PHARMA INC.: OPERATING SEGMENTS
TABLE 82. ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO
TABLE 83. ASTELLAS PHARMA INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 84. ASTRAZENECA PLC: KEY EXECUTIVES
TABLE 85. ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 86. ASTRAZENECA PLC: OPERATING SEGMENTS
TABLE 87. ASTRAZENECA PLC: PRODUCT PORTFOLIO
TABLE 88. ASTRAZENECA PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 89. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
TABLE 90. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 91. BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
TABLE 92. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 93. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 94. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 95. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 96. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
TABLE 97. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 98. F. HOFFMANN-LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 99. JOHNSON AND JOHNSON: KEY EXECUTIVES
TABLE 100. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
TABLE 101. JOHNSON AND JOHNSON: OPERATING SEGMENTS
TABLE 102. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
TABLE 103. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 104. MERCK AND CO., INC.: KEY EXECUTIVES
TABLE 105. MERCK AND CO., INC.: COMPANY SNAPSHOT
TABLE 106. MERCK AND CO., INC.: OPERATING SEGMENTS
TABLE 107. MERCK AND CO., INC.: PRODUCT PORTFOLIO
TABLE 108. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 109. NOVARTIS AG: KEY EXECUTIVES
TABLE 110. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 111. NOVARTIS AG: OPERATING SEGMENTS
TABLE 112. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 113. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 114. PFIZER INC.: KEY EXECUTIVES
TABLE 115. PFIZER INC.: COMPANY SNAPSHOT
TABLE 116. PFIZER INC.: OPERATING SEGMENTS
TABLE 117. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 118. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
FIGURE 1. GLOBAL ONCOLOGY-CANCER DRUGS MARKET, 2024 - 2033
FIGURE 2. SEGMENTATION OF ONCOLOGY-CANCER DRUGS MARKET, 2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN ONCOLOGY-CANCER DRUGS MARKET
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALONCOLOGY-CANCER DRUGS MARKET
FIGURE 10. GLOBAL ONCOLOGY-CANCER DRUGS MARKET SEGMENTATION, BY DRUG CLASS
FIGURE 11. ONCOLOGY-CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 12. ONCOLOGY-CANCER DRUGS MARKET FOR TARGETED THERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 13. ONCOLOGY-CANCER DRUGS MARKET FOR IMMUNOTHERAPY (BIOLOGIC THERAPY), BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 14. ONCOLOGY-CANCER DRUGS MARKET FOR HORMONAL THERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 15. GLOBAL ONCOLOGY-CANCER DRUGS MARKET SEGMENTATION, BY INDICATION
FIGURE 16. ONCOLOGY-CANCER DRUGS MARKET FOR LUNG CANCER, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 17. ONCOLOGY-CANCER DRUGS MARKET FOR STOMACH CANCER, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 18. ONCOLOGY-CANCER DRUGS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 19. ONCOLOGY-CANCER DRUGS MARKET FOR BREAST CANCER, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 20. ONCOLOGY-CANCER DRUGS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 21. ONCOLOGY-CANCER DRUGS MARKET FOR LIVER CANCER, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 22. ONCOLOGY-CANCER DRUGS MARKET FOR ESOPHAGUS CANCER, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 23. ONCOLOGY-CANCER DRUGS MARKET FOR CERVICAL CANCER, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 24. ONCOLOGY-CANCER DRUGS MARKET FOR KIDNEY CANCER, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 25. ONCOLOGY-CANCER DRUGS MARKET FOR BLADDER CANCER, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 26. ONCOLOGY-CANCER DRUGS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 27. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 28. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 29. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 30. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 31. COMPETITIVE DASHBOARD
FIGURE 32. COMPETITIVE HEATMAP: ONCOLOGY-CANCER DRUGS MARKET
FIGURE 33. TOP PLAYER POSITIONING, 2023
FIGURE 34. ABBVIE INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 35. ABBVIE INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 36. ABBVIE INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 37. AMGEN: NET SALES, 2021-2023 ($BILLION)
FIGURE 38. AMGEN: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 39. AMGEN: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 40. ASTELLAS PHARMA INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 41. ASTELLAS PHARMA INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 42. ASTELLAS PHARMA INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 43. ASTRAZENECA PLC: NET SALES, 2021-2023 ($BILLION)
FIGURE 44. ASTRAZENECA PLC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 45. ASTRAZENECA PLC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 46. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2021-2023 ($BILLION)
FIGURE 47. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 48. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 49. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2021-2023 ($BILLION)
FIGURE 50. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 51. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 52. JOHNSON AND JOHNSON: NET SALES, 2021-2023 ($BILLION)
FIGURE 53. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 54. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 55. MERCK AND CO., INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 56. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 57. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 58. NOVARTIS AG: NET SALES, 2021-2023 ($BILLION)
FIGURE 59. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 60. NOVARTIS AG: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 61. PFIZER INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 62. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 63. PFIZER INC.: REVENUE SHARE, BY REGION, 2023 (%)

$5,769
$7,412

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings